ClinicalTrials.gg
Not yet recruitingNCT07814417Updated Oct 15, 2026

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

A Phase 2 interventional study of Olomorasib and Cetuximab in Colorectal Neoplasms, sponsored by Eli Lilly and Company. Not yet recruiting at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026First sites in China, Spain and United States18 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Colorectal Neoplasms by Eli Lilly and Company — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Eli Lilly and Company.

Planned enrollment
23rd of 34
50 · median 103
Started
2026
the only one that year
Phase 2
16 of 37
1 open now
Registered
37th of 37
by date

Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 23rd largest by planned enrollment of the 34 interventional ones that give a count, is the only one that started in 2026, is one of 16 in phase 2, and was the 37th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 37 studies in Colorectal Neoplasms by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Colorectal Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate how well olomorasib is tolerated and what side effects may occur when combined with other interventions in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutant, locally advanced colorectal cancer (CRC) that cannot be removed with surgery or has spread to other parts of the body. Blood tests will be performed to investigate how the body processes the study drug.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed colorectal cancer (CRC) with Stage III or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
  • Must have disease with evidence of KRAS G12C mutation
  • Have per v1.1.
  • Have an (ECOG) performance status of 0 or 1.
  • Ability to swallow capsules.
  • Have adequate laboratory parameters.
  • Have not received treatment for their CRC that has spread to other parts of the body.

    • 1-2 cycles of FOLFOX prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated.

Exclusion criteria

Exclusion Criteria:

  • Have active inflammatory bowel disease requiring medication or previous clear history of inflammatory bowel disease.
  • Have a active malabsorption syndrome or other conditions likely to affect gastrointestinal absorption of the orally administered study treatments.
  • Have known untreated active central nervous system or carcinomatous meningitis.
  • Have known additional that is progressing or has required treatment within the past 2 years.
  • Have uncontrolled, significant cardiovascular disease or cerebrovascular disease.
  • Have an active fungal, bacterial, or active, untreated viral infection.
  • Have (HIV) with a history of Kaposi's sarcoma or Multicentric Castleman's Disease.
  • Have known B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E gene mutation.
  • Have confirmed Microsatellite Instability-High/deficient Mismatch Repair (MSI-H/dMMR).
  • Individuals with known low or absent dihydropyrimidine dehydrogenase activity.
  • Have known positive Immunoglobulin E (IgE) antibodies against galactose-α-1,3-galactose (alpha-gal).
  • Have received adjuvant, , concurrent chemoradiotherapy, or consolidation therapy if treatment was completed less than 6 months prior to enrollment.
  • Are pregnant, breastfeeding, or intend to become pregnant during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Olomorasib + Cetuximab + mFOLFOX6

    Olomorasib administered orally; Cetuximab, fluorouracil, leucovorin \& oxaliplatin administered intravenously (IV)

    Drug: Olomorasib · Drug: Cetuximab · Drug: Oxaliplatin · Drug: Leucovorin/levofolinate calcium · Drug: 5-fluorouracil

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 15 Months)

  2. Progression-Free Survival (PFS) Per RECIST v1.1

    Time frame: Baseline to the Date of First Documented Progression of Disease or Participant Stops Study (Estimated up to 21 Months)

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Baseline through End of Study (Estimated up to 21 months)

  2. Duration of Response (DoR)

    Time frame: Baseline up to 15 months

  3. Disease Control Rate (DCR)

    Time frame: Baseline up to 15 months

  4. Time to Response (TTR)

    Time frame: Baseline up to 15 months

  5. Pharmacokinetics (PK): Plasma Concentrations of Olomorasib (LY3537982)

    Time frame: Baseline up to 2 months

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2028, 25 months later.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 25 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 11, 2026
StartEst.
Oct 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added — first sites in China, Spain and United States
Show 18 added (9 United States, 8 Spain, 1 China)
  • University of Alabama at Birmingham · Birmingham, United States
  • USC Norris Comprehensive Cancer Center · Los Angeles, United States
  • AdventHealth Orlando · Orlando, United States
  • Dana-Farber Cancer Institute · Boston, United States
  • START Astera, LLC · East Brunswick, United States
  • Texas Oncology - Central South · Austin, United States
  • Virginia Cancer Specialists · Fairfax, United States
  • Inova Health Care Services · Falls Church, United States
  • University of Wisconsin - Carbone Cancer Center · Madison, United States
  • Beijing Cancer hospital · Beijing, China
  • Hospital del Mar · Barcelona, Spain
  • Hospital Universitari Quiron Dexeus Barcelona · Barcelona, Spain
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Complejo hospitalario de Jaen · Jaén, Spain
  • Clinica Universidad de Navarra - Madrid · Madrid, Spain
  • Hospital Universitario de Canarias · Santa Cruz de Tenerife, Spain
  • Hospital Universitario Marques De Valdecilla · Santander, Spain
  • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    18 sites added — first sites in China, Spain and United States
    Show 18 added (9 United States, 8 Spain, 1 China)
    • University of Alabama at Birmingham · Birmingham, United States
    • USC Norris Comprehensive Cancer Center · Los Angeles, United States
    • AdventHealth Orlando · Orlando, United States
    • Dana-Farber Cancer Institute · Boston, United States
    • START Astera, LLC · East Brunswick, United States
    • Texas Oncology - Central South · Austin, United States
    • Virginia Cancer Specialists · Fairfax, United States
    • Inova Health Care Services · Falls Church, United States
    • University of Wisconsin - Carbone Cancer Center · Madison, United States
    • Beijing Cancer hospital · Beijing, China
    • Hospital del Mar · Barcelona, Spain
    • Hospital Universitari Quiron Dexeus Barcelona · Barcelona, Spain
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Complejo hospitalario de Jaen · Jaén, Spain
    • Clinica Universidad de Navarra - Madrid · Madrid, Spain
    • Hospital Universitario de Canarias · Santa Cruz de Tenerife, Spain
    • Hospital Universitario Marques De Valdecilla · Santander, Spain
    • Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07814417
Responsible party
Sponsor
First posted
Sep 11, 2026
Start date
Oct 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olomorasib

Start the discussion